150 related articles for article (PubMed ID: 29694292)
1. The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use.
Almodovar AS; Axon DR; Coleman AM; Warholak T; Nahata MC
J Manag Care Spec Pharm; 2018 May; 24(5):416-422. PubMed ID: 29694292
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Comprehensive Medication Review Completion Rates Using 3 Patient Outreach Models.
Miller DE; Roane TE; Salo JA; Hardin HC
J Manag Care Spec Pharm; 2016 Jul; 22(7):796-800. PubMed ID: 27348280
[TBL] [Abstract][Full Text] [Related]
3. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Medication Reviews in Long-term Care Facilities: History of Process Implementation and 2015 Results.
O'Shea TE; Zarowitz BJ; Erwin WG
J Manag Care Spec Pharm; 2017 Jan; 23(1):22-26. PubMed ID: 28025922
[TBL] [Abstract][Full Text] [Related]
5. Positive Medication Changes Resulting from Comprehensive and Noncomprehensive Medication Reviews in a Medicare Part D Population.
Buhl A; Augustine J; Taylor AM; Martin R; Warholak TL
J Manag Care Spec Pharm; 2017 Mar; 23(3):388-394. PubMed ID: 28230451
[TBL] [Abstract][Full Text] [Related]
6. Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment before and after Implementation of Quality-Related Bonus Payments in 2012.
Li P; Doshi JA
PLoS One; 2016; 11(5):e0154357. PubMed ID: 27149092
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
[No Abstract] [Full Text] [Related]
8. Do comprehensive medication review completion rates predict medication use and management quality?
Wang Y; Farley JF; Ferreri SP; Renfro CP
Res Social Adm Pharm; 2019 Apr; 15(4):417-424. PubMed ID: 30917893
[TBL] [Abstract][Full Text] [Related]
9. Online Provision of Part D Medication Therapy Management Program Information.
Tong Z; Cooke CE; Brandt NJ
J Manag Care Spec Pharm; 2019 Aug; 25(8):898-903. PubMed ID: 31347982
[TBL] [Abstract][Full Text] [Related]
10. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region.
Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH
J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396
[TBL] [Abstract][Full Text] [Related]
11. Is There a Relationship Between Part D Medication Adherence and Part C Intermediate Outcomes Star Ratings Measures?
Ta JT; Erickson SC; Qiu WA; Patel BV
J Manag Care Spec Pharm; 2016 Jul; 22(7):787-95. PubMed ID: 27348279
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Medication Therapy Management Services and Their Effects on Health Care Utilization and Medication Adherence.
Ferries E; Dye JT; Hall B; Ndehi L; Schwab P; Vaccaro J
J Manag Care Spec Pharm; 2019 Jun; 25(6):688-695. PubMed ID: 31134865
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an integrated adherence program aimed to increase Medicare Part D star rating measures.
Leslie RS; Tirado B; Patel BV; Rein PJ
J Manag Care Spec Pharm; 2014 Dec; 20(12):1193-203. PubMed ID: 25443513
[TBL] [Abstract][Full Text] [Related]
14. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior.
Leslie RS; Gilmer T; Natarajan L; Hovell M
J Manag Care Spec Pharm; 2016 May; 22(5):526-38. PubMed ID: 27123914
[TBL] [Abstract][Full Text] [Related]
15. Associations Between Chronic Disease, Polypharmacy, and Medication-Related Problems Among Medicare Beneficiaries.
Almodóvar AS; Nahata MC
J Manag Care Spec Pharm; 2019 May; 25(5):573-577. PubMed ID: 31039057
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Eligibility Criteria Used to Identify Patients for Medication Therapy Management Services: A Retrospective Cohort Study in a Medicare Advantage Part D Population.
Lee JS; Yang J; Stockl KM; Lew H; Solow BK
J Manag Care Spec Pharm; 2016 Jan; 22(1):22-30. PubMed ID: 27015048
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the Comprehensive Medication Review Completion Rate for Medicare Part D Plans: What Do the Stars Tell Us?
Cooke CE; Olshanskaya S; Lee M; Brandt NJ
Sr Care Pharm; 2022 Aug; 37(8):357-365. PubMed ID: 35879850
[No Abstract] [Full Text] [Related]
18. The effects of coding intensity in Medicare Advantage on plan benefits and finances.
Jacobs PD; Kronick R
Health Serv Res; 2021 Apr; 56(2):178-187. PubMed ID: 33165932
[TBL] [Abstract][Full Text] [Related]
19. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
20. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
